| Drug Name | Eligard (leuprorelin acetate depot injection) |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Urology
|
| Risk |
Risk of lack of efficacy due to incorrect reconstitution and administration process |
| Dear Healthcare provider letter DHPC |
|